Biogen’s Aduhelm Price Tag Too High Says ICER

The Institute for Clinical and Economic Review (ICER) published a revised report on Biogen’s Aduhelm. The drug is designed for use in Alzheimer’s disease. ICER notes uncertainty regarding the drug’s efficacy and that the $56,000 price tag is much too high.

“Assuming a level of efficacy suggested by blending results from the company’s two Phase 3 trials, one of which failed, ICER calculated treatment would be cost effective only at prices between about $3,000 and $8,400, a reduction of 85% to 95%.” Read more here.

(Source: Ned Pagliarulo, BioPharma Dive, 6/30/21)